PolyPeptide Group is one of the three large peptide contract development and manufacturing organizations supplying the GLP-1 and broader peptide-therapeutics pipeline, alongside Bachem and CordenPharma. The Swedish-Swiss CDMO operates manufacturing sites in Malmö (Sweden), Limhamn (Sweden), Strasbourg (France), Braine-l'Alleud (Belgium), and Torrance (US). In January 2025, PolyPeptide announced a EUR 100M ($113M) expansion to double solid-phase peptide synthesis (SPPS) capacity at its Malmö site; in May 2026 the company expanded its credit facility to EUR 200M to support the strategic plan to double 2023 revenue by 2028.
The demand wave PolyPeptide is positioning against is the incretin-class peptide pipeline: semaglutide and tirzepatide active pharmaceutical ingredient at commercial scale, retatrutide and amycretin at IND through Phase 3 scale, plus peptide-drug conjugates, AMPs, and the next-generation NK2R and amylin programs. The Capital Markets Day commentary positioned PolyPeptide for a 2028 capacity build matching the projected peptide-therapeutics market.
Stories here cover capacity expansions, credit facilities and capital raises, customer wins, and the broader peptide CDMO build-out alongside Bachem, CordenPharma, AmbioPharm, and Gilead Sciences. See #peptide-cdmo, #bachem, and #cordenpharma for adjacent threads.
SNS Insider published its 2026 Peptide Synthesis Market Report on Tuesday May 19, projecting the global peptide synthesis market to reach $1,889.88M by 2035 from current levels, anchored on GLP-1 receptor agonist demand and the broader peptide therapeutics pipeline. The report tracks the major SPPS capacity expansions: CordenPharma's $500M+ Boulder Colorado site adding 25,000L+ to reach 42,000L total by 2028, Bachem's three-site expansion (Bubendorf Switzerland, St Helens UK, Vista California) plus a new Sisseln Switzerland facility, and PolyPeptide's €200M credit facility supporting the doubling of 2023 revenue by 2028. The structural read: incretin-class peptide demand (semaglutide, tirzepatide, retatrutide, mazdutide, survodutide, eleglipron) plus the next-generation pipeline (NK2R agonists, amylin combos, peptide-drug conjugates) is the demand wave the CDMOs are positioning against.
TIDES USA 2026 wrapped at the Hynes Convention Center in Boston on Thursday May 14 after four days of peptide and oligonucleotide CDMO programming. The CMC strategy tracks featured Bachem, PolyPeptide, CordenPharma, AmbioPharm, and Gilead on GMP capacity, large-scale SPPS economics, and the supply-chain economics of oral macromolecule manufacturing. The closing-day Robert Langer keynote framed peptide-LNP delivery as the next major engineering frontier. The conference concluded with Catalent's Zydis fast-dispersion + oral macromolecule platform presentations and Novo Nordisk's CMC strategy panel on oral semaglutide and the next-generation amycretin program. The week's combined manufacturing footprint (TIDES + the PolyPeptide EUR 200M credit facility on May 9 + the May 6 Lilly Lebanon $4.5B investment) anchors the CDMO buildout heading toward the 2028 capacity targets.
ResearchAndMarkets released a Peptide and Oligonucleotide CDMO Market Research Report on April 30 forecasting the global market expanding from $2.42B in 2025 to $2.7B in 2026 (11.9% CAGR), reaching $4.03B by 2030. The report names Bachem, PolyPeptide, CordenPharma, and AmbioPharm as the dominant capacity holders capturing roughly 55–60% of global revenue. Demand for GLP-1 receptor agonists and siRNA drugs is outpacing GMP suite availability, giving CDMOs unusual pricing power in multi-year capacity contracts. The report frames manufacturing capacity as the binding constraint on the next wave of peptide therapeutics.